Skip to content

Clinical study on the treatment of attention deficit hyperactivity disorder in children with Longmu Ningxin Formula

Clinical study on the treatment of attention deficit hyperactivity disorder in children with Longmu Ningxin Formula

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200061786
Enrollment
Unknown
Registered
2022-07-02
Start date
2022-07-15
Completion date
Unknown
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention Deficit Hyperactivity Disorder

Interventions

Chinese Medicine Group:Oral Herbal Medicine
Western medicine group:Focus on Da

Sponsors

Longhua Hospital, Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Years to 14 Years

Inclusion criteria

Inclusion criteria: 1. Meet the Western medical diagnosis of attention deficit hyperactivity disorder in children and Chinese medicine identification criteria; 2. Age 6-14 years old; 3. Not taking other attention deficit hyperactivity disorder-related Western and Chinese medication 2 weeks before entering the clinical study; 4. Not participating in other clinical trials; 5. Informed consent and able to accept the prescribed treatment regimen (e.g., duration of medication, frequency of visits,etc.).

Exclusion criteria

Exclusion criteria: 1. Those who do not meet the inclusion criteria; 2. Those with a combination of serious organic diseases such as cardiovascular (especially those with structural abnormalities of cardiac function), hepatic, renal, hematopoietic, and neurological (epilepsy); 3. hyperactivity symptoms resulting from severe psychological and psychiatric disorders such as mental retardation, autism spectrum disorder, pervasive developmental disorder, childhood schizophrenia, mania, specific learning skills developmental disorder, etc; 4. Hearing or visual impairment; 5. allergy to the test drug; 6. those who participated in clinical trials of other drugs within the last 3 months; 7. Those who, in the judgment of the physician, are prone to lost visits; 8. Patients who have used monoamine oxidase inhibitors within the last 2 weeks; 9. Patients with severe gastrointestinal strictures (pathologic or medically induced), dysphagia, or significant difficulty swallowing pills; 10. Patients with glaucoma, patients with Tourette's syndrome.

Design outcomes

Primary

MeasureTime frame
SNAP-IV?Conners?Weiss;Chinese Medicine Evidence Scoring Scale;

Countries

China

Contacts

Public ContactYonghong Jiang

Longhua Hospital

1536671244@qq.com+86 13764521097

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026